Combining ams’ spectral sensor technology with Precision Biomonitoring’s lateral flow and digital capabilities, the partnership, say the companies, is expected to re-imagine mass testing devices for Covid-19 (SARS-CoV-2). The companies are investigating the efficacy and sensitivity of a lab-free lateral-flow test connected to a medical cloud to detect virus particles in as little as around 15 minutes. The test is focused on detecting the virus at earlier stages of infection, before symptoms have appeared.
The ams spectral sensor solution, says the company, allows fluorescence-based read out of antigen detection, strengthening its leadership in delivering high-quality professional health diagnostics, designed to improve speed and reliability of rapid, point-of-care diagnostics.
"Governments and authorities need to enable fast, reliable and effective testing." says Jennifer Zhao, Executive Vice President, division Advanced Optical Sensors, ams. "Our initial results for this solution indicate that even asymptomatic patients who carry the virus could be more readily identified."
"We expect the combination of Precision Biomonitoring and ams technology to become an essential tool in the effort to help control the pandemic and resume the many economic and social activities that comprise what we call normal life," says Zhao. "This is aided by the fact that, once approved, the testing solution can be produced inexpensively and without complex limitations at high scale. We hope that this solution will eliminate complicated logistics and clinical processes and streamline approaches to mass testing."
Dr. Mario Thomas, CEO, Precision Biomonitoring adds, "The pandemic is still with us and will continue to be part of our lives well into the new year. This partnership with ams will continue to provide innovative solutions urgently needed by government and authorities to help track and control this virus. We are dedicated to developing quality testing devices and with the addition of this highly-sensitive technology we will continue to change the testing landscape."